0001562180-18-004642.txt : 20181121
0001562180-18-004642.hdr.sgml : 20181121
20181121162132
ACCESSION NUMBER: 0001562180-18-004642
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181119
FILED AS OF DATE: 20181121
DATE AS OF CHANGE: 20181121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yoo Stephen
CENTRAL INDEX KEY: 0001652825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 181198433
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC,
STREET 2: 9600 BLACKWELL ROAD, SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2018-11-19
false
0001590877
REGENXBIO Inc.
RGNX
0001652825
Yoo Stephen
C/O REGENXBIO INC.
9600 BLACKWELL ROAD, SUITE 210
ROCKVILLE
MD
20850
false
true
false
false
Chief Medical Officer
Common Stock
2018-11-19
4
M
false
20414.00
0.85
A
20414.00
D
Common Stock
2018-11-19
4
S
false
2761.00
57.08
D
17653.00
D
Common Stock
2018-11-19
4
S
false
2300.00
58.37
D
15353.00
D
Common Stock
2018-11-19
4
S
false
9092.00
59.61
D
6261.00
D
Common Stock
2018-11-19
4
S
false
4361.00
60.25
D
1900.00
D
Common Stock
2018-11-19
4
S
false
800.00
61.55
D
1100.00
D
Common Stock
2018-11-19
4
S
false
1100.00
63.21
D
0.00
D
Employee Stock Option (Right to Buy)
0.85
2018-11-19
4
M
false
20414.00
0.00
D
2024-11-03
Common Stock
20414.00
61244.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $56.79 to $57.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $57.90 to $58.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $58.91 to $59.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $59.93 to $60.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $61.02 to $61.845. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.80 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2018-11-21